Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy

BMC Psychiatry

Manal S Ihbeasheh¹  Ansam F Sawalha¹  Sa’ed H Zyoud¹  Jihad Bani Odeh¹  Waleed M Sweileh¹ 

[1] Division of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine

关键词: Palestine;    Prescribing pattern;    Antipsychotics;   

Others  :  1124014
DOI  :  10.1186/1471-244X-13-179

 received in 2012-08-09, accepted in 2013-06-28,  发布年份 2013

【 摘 要 】

Background

Analysis of the prescribing patterns of antipsychotic drugs can improve therapeutic outcomes. The purpose of this study was to evaluate the prescribing pattern of antipsychotics and its conformance to international treatment guidelines.

Methods

A cross sectional study at primary psychiatric centers was carried out. Patients’ medical files were used to obtain demographic, medication and clinical information. International guidelines for schizophrenia were used to create conformance indicators. All statistical analyses were conducted using Statistical Package for Social Sciences.

Results

250 patients were included in this study. A total of 406 antipsychotic agents were used; 348 (85.7%) were first generation antipsychotics (FGA). The prevalence of antipsychotic combination was 50.4% (n=126). There was no significant difference in positive (p=0.3), negative (p=0.06) and psychopathology (p=0.5) scores of schizophrenia symptoms among patients on monotherapy versus those on antipsychotic combination. Furthermore, no significant difference was observed in the annual cost of antipsychotic monotherapy versus combination therapy. One hundred and five patients (42%) were using optimum dose of (300 – 600 mg CPZeq) while the remaining were using sub or supra therapeutic doses. Analysis showed that use of depot, use of anticholinergic agents and increasing amount of total CPZeq were significant factors associated with antipsychotic combination.

Conclusions

This study indicated that antipsychotic prescribing was not in conformance with international guidelines with respect to maintenance dose and combination therapy. Type of antipsychotic treatment regimen, combination versus monotherapy, was not associated with better clinical or economic outcome.

【 授权许可】

   
2013 Sweileh et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Okasha A, Karam E, Okasha T: Mental health services in the Arab world. World Psychiatry 2012, 11(1):52-54.
• [2]Jaalouk D, Okasha A, Salamoun MM, Karam EG: Mental health research in the Arab world. Soc Psychiatry Psychiatr Epidemiol 2012, 47(11):1727-1731.
• [3]Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS: Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005, 187:248-255.
• [4]APA: Practice guideline for the treatment of patients with schizophrenia. American psychiatric association. Am J Psychiatry 1997, 154(4 Suppl):1-63.
• [5]Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, et al.: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004, 30(2):193-217.
• [6]Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, et al.: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007, 68(11):1751-1762.
• [7]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223.
• [8]Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63(10):1079-1087.
• [9]NICE: National Institute for Health and Care Excellence. CG 82. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update); 2011. http://www.nice.org.uk/CG82 webcite (accessed 27 March 2013)
• [10]Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, et al.: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2009, 36(1):71-93.
• [11]Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64(6):663-667.
• [12]Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS: Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther 2008, 46(5):245-251.
• [13]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
• [14]Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988, 23(1):99-110.
• [15]Adeponle AB, Obembe AO, Adeyemi SO, Suleiman GT: Polypharmacy in psychiatric out-patient practice in northern Nigeria. Afr J Psychiatry (Johannesbg) 2007, 10(4):215-218.
• [16]Koen L, Magni P, Niehaus DJ, le Roux A: Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr J Psychiatry (Johannesbg) 2008, 11(4):287-290.
• [17]Procyshyn RM, Kennedy NB, Tse G, Thompson B: Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001, 46(4):334-339.
• [18]Procyshyn RM, Thompson B: Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 2004, 37(1):12-17.
• [19]Ramadas S, Kuttichira P, Sumesh TP, Ummer SA: A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country. Indian J Psychol Med 2010, 32(1):13-16.
• [20]Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS: Clinical and social determinants of antipsychotic polypharmacy for chinese patients with shizophrenia. pharmocopsychitry 2007, 40:47-52.
• [21]Satake N, Hazama K, Sono T, Takahashi M, Ito J: Changes in antipsychotic medication in clients of assertive community treatment in Japan: a one-year follow up. Clin Pract Epidemiol Ment Health 2011, 19(7):1-3.
• [22]Xiang Y, Weng Y, Leung C, Tang W, Ungvari G: Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007, 40(2):47-52.
• [23]Ganguly R, Kotzan J, Miller L, Kennedy K, Martin B: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry 2004, 65(10):1377-1388.
• [24]Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, Chung EK, Tsang HY, Chan YH, et al.: Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004, 58(2):178-183.
• [25]Taylor DMS, Mace S, Whiskey E: Co-prescribing of atypical and typical antipsychotics - prescribing sequence and documented outcome. Psychiatr Bull 2002, 26:170-2.
• [26]Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007, 89(1–3):91-100.
• [27]Honer W, Thornton A, Chen E, Chan R, Wong J, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna P, Stip E, et al.: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006, 354(5):472-482.
• [28]Shim J, Shin J, Kelly D, Jung D, Seo Y, Liu K, Shon J, Conley R: Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007, 164(9):1404-1410.
• [29]Agelink M, Kavuk I, Ak I: Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004, 161(5):924-925.
• [30]Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC: Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007, 58(4):489-495.
• [31]Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA: Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006, 57(8):1094-1101.
• [32]Hong I, Bishop J: Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother 2010, 44(7–8):1171-1180.
• [33]Xiang Y, Wang C, Si T, Lee E, He Y, Ungvari G, Chiu H, Yang S, Chong M, Tan C, et al.: Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry 2011, 44(3):114-118.
• [34]Lehman AF, Steinwachs DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998, 24(1):11-20. discussion 20–32
• [35]Chen RS, Nadkarni PM, Levin FL, Miller PL, Erdos J, Rosenheck RA: Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia. Psychiatr Serv 2000, 51(6):791-794.
• [36]Hayhurst K, Drake R, Lewis S: Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia. J Psychopharmacol 2010, 24(1):83-89.
• [37]Barnes T, Paton C: Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 2011, 25(5):383-399.